SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  November 16, 2004

NEUROMETRIX, INC.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: (781) 890-9989

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02   Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

The Board of Directors of NeuroMetrix, Inc. (the “Company”) increased its size to six members and appointed Charles R. LaMantia, Ph. D. to serve as a new member of the Board effective as of November 16, 2004. Dr. LaMant ia will serve as a Class II Director with a term expiring in 2006. Dr. LaMantia is expected to serve on the audit committee of the Board; however, the Board has not yet determined on which committees Dr. LaMantia will serve. On November 16, 2004, NeuroMetrix, Inc. issued a press release regarding the appointment of Dr. LaMantia.  The full text of the press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

Item 9.01.  Financial Statements and Exhibits.

(c)  Exhibits.

99.1                                       Press Release of NeuroMetrix, Inc. dated November 16, 2004.

[Remainder of page left blank intentionally]

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be filed on its behalf by the undersigned hereunto duly authorized.

NEUROMETRIX, INC.

Exhibit Index

99.1                                        Press Release of NeuroMetrix, Inc. dated November 16, 2004.

Exhibit 99.1

Press Release-For Immediate Release

NeuroMetrix, Inc. Expands Board of Directors with Addition of Charles R. LaMantia, Ph.D.

WALTHAM, Mass.—(BUSINESS WIRE)—November 16, 2004—NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the design, development and sale of proprietary products used to diagnose neuropathies, announced today that its Board of Directors has appointed Charles R. LaMantia, Ph.D., as a new member of the Company’s Board of Directors effective today.  It is intended that Dr. LaMantia will also serve on the Company’s audit committee.

Dr. LaMantia has over thirty years of experience in business and technology.  He currently serves on the Board of Directors of the State Street Corporation, including as chairman of the audit committee.  He is also a member of the Corporation of Woods Hole Oceanographic Institute and of the Advisory Board of the Carroll School of Management, Boston College.  He retired in July 1999 as Chief Executive Officer, Chairman, and President of Arthur D. Little, Inc., a worldwide professional service firm with activities in management consulting, technology and product development, and environmental, health and safety, a position that he had held since July 1988.    Previously, he spent five years as President and Chief Executive Officer of Koch Process Systems, Inc. (KPS), a wholly owned subsidiary of Koch Industries.  Dr. LaMantia received a B. A. (magna cum laude) and B. S., M. S., and Sc. D. degrees in chemical engineering from Columbia University and completed the Advanced Management Program at Harvard Business School.  He was a Sloan Foundation Fellow, a National Science Foundation Fellow, and is a member of Phi Beta Kappa and Tau Beta Pi.

“We are honored to have an individual with the breadth of experience and achievements of Dr. LaMantia join our Board of Directors,” said Dr. Shai N. Gozani, President and Chief Executive Officer.  “Charlie will bring a wealth of business, management and technical knowledge to NeuroMetrix as we continue to grow the business and build a premier medical device company.”

About NeuroMetrix

NeuroMetrix is a medical device company establishing a new standard of care through the design, development and sale of proprietary products used to diagnose neuropathies. Neuropathies are diseases of the peripheral nerves and parts of the spine that frequently are caused by or associated with diabetes, low back pain and carpal tunnel syndrome, as well as other clinical disorders. The NC-stat System, the Company’s neuropathy diagnostic system, has been on the market since May 1999 and is presently used in over 2,000 physician’s offices, clinics and other health care facilities in the United States. The Company holds issued utility patents covering a number of important aspects of the NC-stat System.

Contact:

                Nicholas J. Alessi

                Director of Finance
                NeuroMetrix, Inc.
                781-890-9989
                neurometrix.ir@neurometrix.com
                SOURCE: NeuroMetrix, Inc.